India Backs AI-Powered Drug Discovery With ₹86 Crore Funding
India is increasing its support for artificial intelligence-driven pharmaceutical research through a new funding agreement designed to move experimental drug candidates closer to clinical development.
The government's Technology Development Board (TDB), operating under the Department of Science and Technology, has signed an agreement with Bengaluru-based Peptris Technologies Private Limited to provide ₹86 crore in financial support under the Research Development and Innovation Fund.
The programme, named VIGOR: Advancing AI-Discovered Molecules from Bench to Clinic, has a total project cost of ₹172 crore. Its goal is to advance four experimental drug candidates through preclinical development, scientific validation and preparation for clinical trials.
The announcement highlights India's growing interest in combining artificial intelligence with biotechnology to discover and develop potential new treatments.
How the ₹172 Crore Project Will Work
The VIGOR programme combines AI-based drug discovery with laboratory testing and established pharmaceutical development processes.
Peptris will use its proprietary artificial intelligence platform to support the development of four drug candidates. The government-backed funding is intended to help bridge the gap between identifying promising molecules computationally and demonstrating that they can progress through the demanding stages of drug development.
The ₹86 crore support will be provided through optionally convertible debt, rather than being described as a conventional grant. The remaining project cost forms part of the overall ₹172 crore programme.
The development plan is expected to run for approximately three years, subject to scientific findings and regulatory requirements.
Four Experimental Drug Candidates in Focus
The project covers four candidates identified by Peptris for further development.
1. PEPR111 for Neuromuscular Disorders and Oncology
PEPR111 is intended for research into neuromuscular disorders and oncology. These are broad therapeutic areas involving complex biological processes and significant unmet medical needs.
Further development and testing will be required to establish the candidate's safety, effectiveness and suitability for any specific medical use.
2. PEPRX101 for Alopecia
PEPRX101 is focused on alopecia, a term used for hair loss. Hair loss can have several causes, and treatment approaches depend on the underlying condition.
The project aims to advance the experimental candidate through additional development and validation. It is not yet an approved treatment for hair loss.
3. PEPR202 for Neuropathy
PEPR202 is being developed for neuropathy, a category of conditions involving damage or dysfunction of nerves.
Neuropathy can be associated with different underlying diseases and may cause symptoms such as pain, numbness or weakness. The candidate will require further scientific and regulatory evaluation before its potential clinical use can be determined.
4. PEPR112 for Duchenne Muscular Dystrophy
PEPR112 is focused on Duchenne muscular dystrophy (DMD), a serious genetic disorder that causes progressive muscle weakness.
Research into DMD remains an important area of medical innovation because the condition can affect mobility, heart function and respiratory muscles over time.
The VIGOR programme aims to advance PEPR112 through additional development milestones. The announcement does not establish that the candidate is effective or safe for patients.
Why Artificial Intelligence Matters in Drug Discovery
Traditional drug discovery can require years of research, laboratory experiments and extensive testing. Researchers must identify promising molecules, investigate how they interact with biological targets and evaluate whether they could eventually become medicines.
Artificial intelligence can help scientists analyse large biological and chemical datasets, identify patterns and prioritise molecules for further investigation.
AI systems can also help researchers explore possible drug-target interactions and narrow down which candidates deserve additional laboratory testing.
However, an AI-generated prediction is not proof that a molecule will work in the human body. Experimental validation remains essential, and potential medicines must undergo rigorous preclinical and clinical evaluation.
From Computer Models to Laboratory Testing
One of the biggest challenges in AI-based pharmaceutical research is moving from a promising computational result to a candidate that can be developed into a real medicine.
A molecule may appear promising in a computer model but perform differently when tested in biological systems. Researchers must examine its properties, potential toxicity, dosage characteristics and other factors before determining whether further development is justified.
The VIGOR programme is intended to support this transition by combining Peptris' AI-based discovery capabilities with experimental validation and established drug-development methods.
The programme also plans to use global contract research organisation networks to support testing and development activities.
What Are Technology Readiness Levels?
The four candidates are currently positioned at Technology Readiness Level 4, with the programme targeting progression to Level 6.
Technology Readiness Levels are used to describe how mature a technology is as it moves from early research toward validation and practical application.
In this project, progression involves additional preclinical studies, validation and preparation for clinical development. Reaching the intended readiness level would represent progress in development, but it would not automatically mean that a candidate has been approved as a medicine.
Clinical trials, regulatory review and other requirements would still need to be addressed according to the relevant development pathway.
Why India Is Investing in AI and Biotechnology
India has a substantial pharmaceutical industry and a growing technology startup ecosystem. Combining these strengths could create opportunities in drug discovery, biotechnology research and the development of new therapeutic products.
AI-based drug discovery is attracting interest because it may help researchers investigate more candidates and prioritise experiments more efficiently. The real-world benefits, however, depend on the quality of the underlying data, the reliability of the models and the results of laboratory and clinical testing.
Government-backed research funding can help companies support expensive development stages that may be difficult to finance through early commercial revenue alone.
The Peptris agreement is part of a wider effort to strengthen India's research and innovation capabilities and support the translation of scientific discoveries into potential products.
The Difference Between Drug Discovery and an Approved Medicine
Although AI can support the identification of potential drug candidates, the discovery stage is only one part of the process required to develop a medicine.
Before a candidate can become an approved treatment, researchers generally need to establish sufficient evidence about its quality, safety and effectiveness through the applicable development and regulatory pathway.
Preclinical studies help researchers assess a candidate before human testing. Clinical trials then evaluate the medicine in people under controlled conditions, subject to ethical and regulatory oversight.
Many experimental candidates do not ultimately become approved medicines. For this reason, the four Peptris candidates should be considered investigational projects rather than established treatments.
What Happens Over the Next Three Years?
The VIGOR programme envisages a structured development process over approximately three years. Planned activities include advanced preclinical studies, investigational new drug-enabling work, formulation development and preparation for clinical trials.
The timing and progression of each candidate will depend on scientific results and applicable regulatory requirements.
If the programme meets its development objectives, it could help move the four candidates closer to the stages required for clinical investigation. It is too early to determine whether any of them will eventually receive approval or become commercially available.
A Growing Role for AI in Pharmaceutical Research
Artificial intelligence is increasingly being explored across the pharmaceutical industry, from analysing biological data to supporting candidate selection and research planning.
Its potential value lies in helping researchers process complex information and focus resources on promising scientific directions. But successful drug development still requires laboratory evidence, clinical research, manufacturing controls and regulatory oversight.
The Peptris programme illustrates how AI-based discovery is being connected to these more demanding stages of pharmaceutical development.
Conclusion
India's ₹86 crore funding agreement with Peptris Technologies marks a new step in the country's support for AI-driven pharmaceutical research.
The ₹172 crore VIGOR programme aims to advance four experimental drug candidates targeting neuromuscular disorders and oncology, alopecia, neuropathy and Duchenne muscular dystrophy.
Over the next three years, the programme plans to combine artificial intelligence, scientific validation and preclinical development to move the candidates closer to clinical investigation.
The outcome remains uncertain, and none of the candidates should be considered an approved treatment on the basis of this announcement alone. Nevertheless, the initiative demonstrates how India is investing in the connection between AI, biotechnology and future medicine development.
Journalist: Vijay Singh